Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders

Blood

Volumn 109, Issue 1, 2007, Pages 61-64

  David, Marianna ^a   Cross, Nicholas C P ^b   Burgstaller, Sonja ^c   Chase, Andrew ^b   Curtis, Claire ^b   Dang, Raymond ^d   Gardembas, Martine ^e   Goldman, John M ^f   Grand, Francis ^b   Hughes, George ^g   Huguet, Francoise ^h   Lavender, Louise ⁱ   McArthur, Grant A ^j   Mahon, Francois X ^k   Massimini, Giorgio ^l   Melo, Junia ^f   Rousselot, Philippe ^m   Russell Jones, Robin J ⁿ   Seymour, John F ^j   Smith, Graeme ^o   Stark, Alastair ^d   Waghorn, Katherine ^b   Nikolova, Zariana ^l   Apperley, Jane F ^f,p   more..

^a UNIVERSITY OF PÉCS   (Hungary)

^b SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^c UNIVERSITY OF VIENNA   (Austria)

^d DUMFRIES AND GALLOWAY ROYAL INFIRMARY   (United Kingdom)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g WEST MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^h CHU PURPAN   (France)

ⁱ SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^j PETER MACCALLUM CANCER CENTRE   (Australia)

^k UNIVERSITÉ DE BORDEAUX   (France)

^l NOVARTIS PHARMA AG   (Switzerland)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ ST THOMAS HOSPITAL   (United Kingdom)

^o LEEDS GENERAL INFIRMARY   (United Kingdom)

^p HAMMERSMITH HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; HYBRID PROTEIN; HYDROXYUREA; IMATINIB; MERCAPTOPURINE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; STEROID;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DOSE RESPONSE; EOSINOPHILIA; FEMALE; FOLLOW UP; HUMAN; MALE; MYELOPROLIFERATIVE DISORDER; PATIENT MONITORING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 33845991464     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-05-024828     Document Type: Article

References (21)

1. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.
2. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947-4952.
3. Apperley JF, Gardembas M, Melo J, et al. Response to imatinib in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481-487.
4. Grand FH, Burgstaller S, Kuhr T, et al. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5; 15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res. 2004;64:7216-7219.
5. Magnusson MK, Meade KE, Nakamura R, Barrett J, Dunbar CE. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood. 2002;100:1088-1091.
6. Garcia JL, Font de Mora J, Hernandez JM, et al. Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. Blood. 2003;102:2699-2700.
7. Pitini V, Arrigo C, Teti D, Barresi G, Righi M, Alo G. Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report. Haematologica. 2003;88:ECR18.
8. Wilkinson K, Velloso ER, Lopes LF, et al. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood. 2003;102:4187-4190.
9. Bastie JN, Garcia I, Terre C, Cross NC, Mahon FX, Castaigne S. Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene. Haematologica. 2004 89:1263-1264.
10. Wittman B, Horan J, Baxter J, et al. A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate. Leuk Res. 2004;28(suppl 1):S65-S69.
11. Vizmanos JL, Novo FJ, Roman JP, et al. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5; 14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res. 2004;64:2673-2676.
12. Levine RL, Wadleigh M, Sternberg DW, et al. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia. 2005;19:27-30.
13. Baxter EJ, Kulkami S, Vizmanos JL, et al. Novel translocations that disrupt the platelet-derived growth factor receptor β (PDGFRB) gene in BCR-ABL negative chronic myeloproliferative disorders. Br J Haematol. 2003;120.2:251-256.
14. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts- for residual disease detection in leukemia: a Europe Against Cancer program. Leukemia. 2003;17:2318-2357.
15. Heldin CH, Eriksson U, Ostman A. New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys. 2002;15:284-290.
16. Kaminski WE, Lindahl P, Lin NL, et al. Basis of hematopoietic defects in platelet-derived growth factor (PDGF)-B and PDGF β-receptor null mice. Blood. 2001;97:1990-1998.
17. Bergsten E, Uutela M, Li X, et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol. 2001;3:512-516.
18. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukaemia with t(5;12) chromosomal translocation. Cell. 1994;77:307-316.
19. Jones AV, Cross NCP. Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci. 2004;61:2912-2923.
20. Steer EJ, Cross NCP. Myeloproliferative disorders with translocations of 5q31-q35: role of the platelet-derived growth factor beta. Acta Haematol. 2002;107:113-122.
21. Kaeda J, O'Shea D, Szydlo RM, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplant for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood. Prepublished on February 7, 2006, as DOI 10.1182/blood-2005-08-3320. (Now available as Blood. 2006;107:4171-4176.)